---
schema_version: "secwatch.filing_event.v1"
accession: "0001739104-26-000008"
form_type: "8-K"
ticker: "ELAN"
cik: "0001739104"
company_name: "Elanco Animal Health Inc"
filed_at: "2026-02-24T23:59:59+00:00"
generated_at: "2026-05-16T00:50:38.430596+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Elanco reports Q4 revenue up 12% to $1.14B, net loss $276M; provides 2026 guidance in line with outlook

## Summary
- Q4 2025 revenue $1,144M (+12% reported, +9% organic CC); reported net loss $276M, adjusted EPS $0.13.
- FY 2025 revenue $4,715M (+6% reported, +7% organic CC); reported net loss $232M, adjusted EPS $0.94.
- 2026 guidance: revenue $4,950-5,020M (4-6% organic CC growth), adjusted EBITDA $955-985M, adjusted EPS $1.00-1.06.
- Raising 2026 innovation revenue target to $1.15B; delivered all 'Big 6' blockbuster products by end of 2025 with Befrena approval in Q4.
- Recorded $155M restructuring charges in Q4 under Elanco Ascend; net leverage ratio improved to 3.6x.

## SEC filing metadata
- accession: 0001739104-26-000008
- form_type: 8-K
- ticker: ELAN
- cik: 0001739104
- company_name: Elanco Animal Health Inc
- filed_at: 2026-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739104/000173910426000008/0001739104-26-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739104/000173910426000008/elan-20260224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001739104-26-000008
- JSON: https://secwatch.observer/filing/0001739104-26-000008.json
- Plain text: https://secwatch.observer/filing/0001739104-26-000008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.